期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

西格列汀治疗老年2型糖尿病的疗效观察 被引量：6

原文传递
导出
摘要 目的探讨西格列汀治疗老年2型糖尿病的疗效和安全性。方法采用随机、安慰剂对照的方法,将选取的60例老年2型糖尿病患者随机分成2组,2组患者均保持原治疗方案基础上,治疗组予以加服西格列汀100mg/次,1次/d;对照组予以加服安慰剂1片/次,1次/d,3个月后观察两组治疗前后空腹血糖(FPG)、餐后2h血糖(2hPG)、糖化血红蛋白(HbA1C)值。对治疗前后上述指标进行对比分析。结果 12周后治疗组FPG、2hPG、HbA1C值均较治疗前明显下降,对照组FPG、2hPG、HbA1C值均无显著变化。结论西格列汀可有效控制老年2型糖尿患者的血糖,降低HbA1C,安全可靠,不良反应小,值得临床推广。
作者 赵迎峰 王晓玲 翟金盛
机构地区 南京军区南京总医院干部保健科
出处 《医药论坛杂志》 2012年第6期84-84,86,共2页 Journal of Medical Forum
关键词 西格列汀 老年 2型糖尿病
分类号 R587.1 [医药卫生—内分泌]
  • 相关文献

参考文献7

二级参考文献33

  • 1蔡乐,朱珠,王强,刘新月.胰岛素类似物与新型降糖激素类药物[J].中国新药杂志,2007,16(6):432-437. 被引量：26
  • 2International Diabetes Federation.Foreword of the Diabetes Atlas(4th edition)[EB/OL].(2009-10-01)[2010-6-16].http://www.diabetesatlas.org/content/foreword-0.
  • 3VanDeKoppel S,Choe HM,Sweet BV.Mana ged care perspective on three new agents for type 2 diabetes[J].J Manag Care Pharm,2008,14(4):363-380.
  • 4Freeman JS.Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus[J].Cleve Clin J Med,2009,76(Suppl 5):S12-S19.
  • 5Todd JF,Bloom SR.Incretins and other peptides in the treatment of diabetes[J].Diabet Med,2007,24(3):223-232.
  • 6Neumiller JJ.Differential chemistry(structure),mechanism of action,and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors[J].J Am Pharm Assoc,2009,49(Suppl 1):S16-S29.
  • 7Tahrani AA,Piya MK,Barnett AH.Saxagliptin:a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus[J].Adv Ther,2009,26(3):249-262.
  • 8Demuth HU,McIntosh CH,Pederson RA.Type 2 diabetestherapy with dipeptidyl peptidase Ⅳ inhibitors[J].Biochem Biophys Acta,2005,1751(1):33-44.
  • 9Kirby M,Yu DM,O'Connor S,et al.Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition[J].Clin Sci(Lond),2009,118(1):31-41.
  • 10Kendall DM,Cuddihy RM,Bergenstal RM.Clinical application of incretin-based therapy:therapeutic potential patient selection and clinical use[J].Ear J Intern Med,2009,20(Suppl 2):S329-S339.

共引文献122

同被引文献41

  • 1宋晓园.中药类降血糖药物药理学研究概况[J].江西中医学院学报,2011,23(3):74-77. 被引量：11
  • 2王巧灵.西格列汀治疗2型糖尿病30例临床观察[J].基层医学论坛,2012,16(S1):58-60. 被引量：2
  • 3何寒青,陈坤.Meta分析中的异质性检验方法[J].中国卫生统计,2006,23(6):486-487. 被引量：104
  • 4陆再英,钟南山.内科学[M].北京:人民卫生出版社,2008:121.
  • 5Lund A,Vilsb ll T,Bagger JI,et al.The separate and combined impact of the intestinal hormones,GIP,GLP-1,and GLP-2,on glucagon secretion in type2diabetes[J].Am J Physiol Endocrinol Metab,2011,300(6):1038.
  • 6Jadad AR,Moore A,Carroll D,et al.Assessing the quali-ty of reports of randomized clinical trials:is blinding nec-essary[J].Control Clin Trials,1996,17(1):1.
  • 7Arechavaleta R,Seck T,Chen Y,et al.Efficacy and safe-ty of treatment with sitagliptin or glimepiride in patients with type2diabetes inadequately controlled on metformin monotherapy:a randomized,double-blind,non-inferiori-ty trial[J].Diabetes Obes Metab,2011,13(2):160.
  • 8Seck T,Nauck M,Sheng D,et al.Safety and efficacy of treatment with sitagliptin or glipizide in patients with type2diabetes inadequately controlled on metformin:a2-year study[J].Int J Clin Pract,2010,64(5):562.
  • 9Bergenstal RM,Wysham C,Macconell L,et al.Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type2diabetes(DURATION-2):a randomised trial[J].Lancet,2010,376(9739):431.
  • 10Rigby SP,Handelsman Y,Lai YL,et al.Effects of cole-sevelam,rosiglitazone,or sitagliptin on glycemic control and lipid profile in patients with type2diabetes mellitus inadequately controlled by metformin monotherapy[J].En-docr Pract,2010,16(1):53.

二级引证文献23

医药论坛杂志
2012年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部